Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
Public ClinicalTrials.gov record NCT01439152. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors
Study identification
- NCT ID
- NCT01439152
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 148 participants
Conditions and interventions
Conditions
Interventions
- BAY94-9343 Drug
- BAY94-9343 (Expansion) Drug
- BAY94-9343 (1.8 mg/kg) Drug
- BAY94-9343 (2.2 mg/kg) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 6, 2011
- Primary completion
- Dec 30, 2016
- Completion
- Jul 29, 2019
- Last update posted
- Jul 8, 2021
2011 – 2019
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | New Haven | Connecticut | 06520-8063 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Bethesda | Maryland | 20892 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Dallas | Texas | 75251 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01439152, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01439152 live on ClinicalTrials.gov.